The generation of induced pluripotent stem (iPS) cells is an innovative approach for generating autologous pluripotent stem cell lines for individualized cell therapy. Our research will use human skeletal muscle derived myoblasts rather than terminally differentiated fibroblasts for non-viral generation of iPS and their differentiation int cardiac progenitor cells. The hypothesis is that skeletal myoblasts (SMs) are superior candidates for induction to pluripotent state with fewer factors either alone or in combination with treatment with small molecules. Thus iPS derived cardiac progenitors may be readily generated with the use of cardiogenic small molecules, purified to generate off shelf universal cardiac cells. The direct generation of progenitors from iPS cells with specific small molecule may be a major current paradigm shift in stem cell therapy. We further propose that use of iPS derived cardiovascular progenitors will allow successful regeneration of infarcted myocardium without the risk of tumorgenecity. The hypotheses will be tested in the following specific Aims.
Specific Aim -1will generate iPS cells from human SMs using small molecules;
Specific Aim -2 will focus on developing strategies to direct iPS cells to cardiac and vascular progenitors;
Specific Aim -3 will exploit the power of Ischemic preconditioning signaling in regulating survival and engraftment of iPS -progenitors in the ischemic tissue for effective regeneration;
Specific Aim 4 will test that transplantation of iPS - progenitors and preconditioned progenitors effectivel regenerates infarcted myocardium and reverses fibrosis in murine and pre-clinical porcine heart models. The end points of the in vivo studies will be reversal of fibrosis through myoangiogenic differentiation of the engrafted progenitor cells, functional integration of developing cardiac myocytes into the host heart, attenuation of infarct size and the functional benefits in terms of improved global heart function. These studies will involve multidisciplinary approach which will employ state of the art molecular biology, histochemical and immunohistochemical techniques and well integrative physiology involving well established experimental animal model, and transthoracic ultrasonography for animal heart function. These studies are expected to facilitate robust cardiac differentiation and cardiomyocyte purification resulting in generation of unlimited number of cardiac progenitor cells from SM-iPS for restoring damaged myocardium without the risk of tumor formation.
Heart disease is a serious health problem in the USA. This proposal is designed to reprogram human skeletal myoblasts to iPS cells without viral vectors and induce them to cardiac progenitors prior to their transplantation into the diseased heart. It i likely that findings of this study will provide strategies towards targeted cell therapies for hear disease.
|Gong, Min; Yu, Bin; Wang, Jingcai et al. (2017) Mesenchymal stem cells release exosomes that transfer miRNAs to endothelial cells and promote angiogenesis. Oncotarget 8:45200-45212|
|Duan, Yuping; Zhu, Wei; Liu, Min et al. (2017) The expression of Smad signaling pathway in myocardium and potential therapeutic effects. Histol Histopathol 32:651-659|
|Matsu-ura, Toru; Sasaki, Hiroshi; Okada, Motoi et al. (2016) Attenuation of teratoma formation by p27 overexpression in induced pluripotent stem cells. Stem Cell Res Ther 7:30|
|Yu, Bin; Yang, Yueting; Liu, Huan et al. (2016) Clusterin/Akt Up-Regulation Is Critical for GATA-4 Mediated Cytoprotection of Mesenchymal Stem Cells against Ischemia Injury. PLoS One 11:e0151542|
|Okada, Motoi; Kim, Ha Won; Matsu-ura, Kaoru et al. (2016) Abrogation of Age-Induced MicroRNA-195 Rejuvenates the Senescent Mesenchymal Stem Cells by Reactivating Telomerase. Stem Cells 34:148-59|
|Cai, Wen-Feng; Huang, Wei; Wang, Lei et al. (2016) Induced Pluripotent Stem Cells derived Muscle Progenitors Effectively Mitigate Muscular Dystrophy through Restoring the Dystrophin Distribution. J Stem Cell Res Ther 6:|